This multiple award IDV was issued by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 to acquire pharmaceuticals and drugs under GSA's Pharmaceuticals and Drugs schedule. Circassia Inc. was awarded the IDV with a potential value of $30.4 million and a period of performance through March 2025.
The IDV facilitates the acquisition of drugs, pharmaceuticals, and hematology-related products through task orders or delivery orders issued against GSA Federal Supply Schedule 65 IB. This schedule provides access to commercial pharmaceuticals, drugs, and related medical and surgical items for the VA healthcare system to support treatment of veterans. The IDV aims to help meet the VA's needs for prescription and over-the-counter medications to treat conditions commonly faced by the veteran patient population.
Generated 1/4/24, 9:52 PM